LFMD

Business Context and Reporting Period

Lifemd, Inc. (LFMD) is a patient-centric, direct-to-patient healthcare company providing virtual medical care and pharmacy services through brands including LifeMD, RexMD, and ShapiroMD. This Form 10-Q covers the quarterly period ended June 30, 2026. The company operates as a single segment and recently sold its majority interest in WorkSimpli (classified as discontinued operations) in November 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 4% quarter-over-quarter (QoQ) and 2% year-over-year (YoY) for the six-month period. The decline was driven by a decrease in telehealth product revenue due to lower online sales demand, partially offset by growth in subscription revenue.
• Expense Increase: Total operating expenses increased 10% QoQ and 16% YoY (six months). Selling and marketing expenses rose significantly (27% QoQ, 30% YoY six months) due to initiatives to drive subscription growth.
• Margin Expansion: Despite revenue declines, gross profit margins improved to 88.8% (Q3) and 88.5% (YTD) compared to 86.0% and 85.0% in the prior year periods, driven by product mix and reduced shipping costs.
• Loss Widening: Net loss attributable to common stockholders widened significantly to $(7.86) million for the quarter and $(17.51) million for the six months, compared to $(2.40) million and $(3.36) million in the prior year periods.
• Discontinued Operations: The prior year periods included net income from discontinued operations (WorkSimpli), which is no longer present in the current period.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Capital Resources: The company reported negative working capital of approximately $4.5 million. Management expects existing cash ($25.1 million) and proceeds from an At-Market (ATM) issuance agreement ($44.6 million available) to fund operations for at least the next 12 months.
• Debt Covenants: The company entered a $30 million credit facility with Citizens Bank in January 2026. It was out of compliance with the Interest Coverage Ratio covenant as of March 31, 2026, but secured a waiver and amendment on June 30, 2026. The amended agreement requires a Fixed Charge Coverage Ratio of 1.25:1 and a minimum cash/availability balance of $40 million starting September 30, 2026.
• Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses in internal control over financial reporting. These weaknesses relate to revenue recognition (agent vs. principal), segregation of duties, and IT general controls. Remediation plans are underway.
• Legal Proceedings: A putative securities class action lawsuit was filed in August 2025 alleging violations of the Exchange Act. A motion to dismiss was filed in March 2026, with opposition and reply briefs filed in May and June 2026.
• Financial Revisions: The company revised previously issued financial statements to correct errors related to revenue recognition and out-of-period adjustments.

Investor Verification Checklist

• Covenant Compliance: Verify the company's ability to meet the new $40 million cash/availability requirement and Fixed Charge Coverage Ratio by September 30, 2026.
• Remediation Progress: Monitor the status of remediation for material weaknesses in internal controls, specifically regarding revenue recognition and IT general controls.
• Marketing ROI: Assess the return on the significant increase in selling and marketing spend (up 30% YoY) against the current revenue decline.
• Legal Exposure: Track the outcome of the pending securities class action lawsuit and related derivative complaints.
• ATM Utilization: Monitor the utilization of the $44.6 million remaining under the ATM Sales Agreement to fund operations.